ALXO — ALX Oncology Holdings Share Price
0.000.00%
Last trade - 00:00- $653.48m
- $482.68m
- 44
- 14
- 87
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.44 | ||
| Price to Tang. Book | 3.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.44% | ||
| Return on Equity | -70.97% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.8 | 1.18 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
Directors
- Corey Goodman CHM (69)
- Jaume Pons PRE
- Peter Garcia CFO (59)
- Shelly Pinto CAO (45)
- Sophia Randolph OTH (53)
- Rekha Hemrajani IND (52)
- Jason Lettmann IND (43)
- Jack Nielsen IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 1st, 2020
- Public Since
- July 17th, 2020
- No. of Shareholders
- 81
- No. of Employees
- 72
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 50,152,082
- Address
- 323 Allerton Avenue, SOUTH SAN FRANCISCO, 94080
- Web
- https://alxoncology.com/
- Phone
- +1 6504667125
- Auditors
- KPMG LLP
Upcoming Events for ALXO
ALX Oncology Holdings Inc Annual Shareholders Meeting
Q2 2024 ALX Oncology Holdings Inc Earnings Release
Similar to ALXO
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the ALX Oncology Holdings share price?
As of Today at 19:02 UTC, shares in ALX Oncology Holdings are trading at $13.03. This share price information is delayed by 15 minutes.
How has the ALX Oncology Holdings share price performed this year?
Shares in ALX Oncology Holdings last closed at $13.03 and the price had moved by +163.23% over the past 365 days. In terms of relative price strength the ALX Oncology Holdings share price has outperformed the S&P500 Index by +112.59% over the past year.
What are the analyst and broker recommendations for ALX Oncology Holdings?
The overall consensus recommendation for ALX Oncology Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ALX Oncology Holdings dividend yield?
ALX Oncology Holdings does not currently pay a dividend.
Does ALX Oncology Holdings pay a dividend?
ALX Oncology Holdings does not currently pay a dividend.
When does ALX Oncology Holdings next pay dividends?
ALX Oncology Holdings does not currently pay a dividend.
How do I buy ALX Oncology Holdings shares?
To buy shares in ALX Oncology Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ALX Oncology Holdings?
As of the previous close price of $13.03, shares in ALX Oncology Holdings had a market capitalisation of $653.48m.
Where are ALX Oncology Holdings shares listed?
Here are the trading details for ALX Oncology Holdings:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALXO
What kind of share is ALX Oncology Holdings?
Based on an overall assessment of its quality, value and momentum ALX Oncology Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ALX Oncology Holdings share price forecast for 2024?
The analyst consensus target price for shares in ALX Oncology Holdings is $20.15. That is 54.64% above the last closing price of $13.03.
Analysts covering ALX Oncology Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$3.27 for the next financial year.
What is the trend in the ALX Oncology Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ALX Oncology Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +21.83%.
As of the last closing price of $13.03, shares in ALX Oncology Holdings were trading +34.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ALX Oncology Holdings PE Ratio?
The ALX Oncology Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $13.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ALX Oncology Holdings?
ALX Oncology Holdings' management team is headed by:
- Corey Goodman - CHM
- Jaume Pons - PRE
- Peter Garcia - CFO
- Shelly Pinto - CAO
- Sophia Randolph - OTH
- Rekha Hemrajani - IND
- Jason Lettmann - IND
- Jack Nielsen - IND